iSBTc 19th Annual Meeting
Annual Meeting Main Page | Award Winners | Download Final Program 
| Faculty | Pictures
Presentation Slides & Schedule | Session & Abstract Topics
| Faculty | PicturesPresentation Slides & Schedule | Session & Abstract Topics
Some presentations are available for viewing. Please select the 
icon to view a presentation.
| Friday, November 5, 2004 | |
| 7:55 am - 8:15 am |
Welcome Address Steven Hirschfeld, MD, PhD FDA Office of Cellular, Tissue and Gene Therapies |
| 8:15 am - 9:00 am | Keynote Address Design and Selection of Vaccine Adjuvants Carl Alving, MD Walter Reed Army Institute of Research |
| 9:00 am - 11:45 am | Plenary Session: Immune Adjuvants Chair(s) Eli Gilboa, PhD Duke University Medical Center Donald L. Morton, MD John Wayne Cancer Institute |
| 9:00 am - 9:30 am | Immunomodulation of Cellular and Humoral Responses During Active
Immunotherapy for Melanoma Donald L. Morton, MD John Wayne Cancer Institute |
| 9:30 am - 10:00 am |
Immunological Adjuvants, the Indispensable Third Component Philip O. Livingston, MD Memorial Sloan-Kettering Cancer Center |
| 10:00 am - 10:15 am |
Regression of Established Autochthonous Mammary Tumors and Induction of
Systemic Anti-Tumor T- and B-Cell Immunity in HER-2/NEU Transgenic Mice
after Treatment with IL-12 and GM-CSF-Encapsulated Microspheres Nejat Egilmez, PhD J.G. Brown Cancer Center |
| 10:15 am - 10:30 am |
Induction of TH1-Type Immunity and Tumor Protection with a Prostate
Specific Antigen DNA Vaccine and pIL-18 Adjuvant Therapy Deborah J. Marshall, PhD Centocor, Inc. |
| 11:00 am - 11:15 am | Adjuvant Effect of Topical Imiquimod Compared to Intradermal GM-CSF on
the Cellular Composition of Draining Lymph Nodes Wolfgang M. Wagner, PhD University of Washington |
| 11:15 am - 11:45 am | Therapeutic Vaccination with mRNA Transfected Dendritic Cells
Eli Gilboa, PhD Duke University Medical Center |
| 11:45 am - 1:00 pm | Odd Number Poster Presentations/Box Lunches |
| 1:00 pm - 3:00 pm | Plenary Session: Adoptive Immunotherapy Chair(s) Bernard A. Fox, PhD Earle A. Chiles Research Institute Patrick Hwu, MD MD Anderson Cancer Center |
| 1:00 pm - 1:15 pm |
Adoptive Immunotherapy of Cancer with Polyclonal Hyperexpanded CD4 and
CD8 T Cells Derived from Tumor-Draining Lymph Nodes Gregory E. Plautz, MD Cleveland Clinic Foundation |
| 1:15 pm - 1:30 pm |
Therapeutic Efficacy of MUC1-Specific Cytotoxic T Lymphocytes and CD137
Co-Stimulation in a Spontaneous Mammary Cancer Model Pinku Mukherjee, PhD Mayo Clinic Scottsdale |
| 1:30 pm - 2:00 pm | Enhanced Antitumor Effects Using Dendritic Cells to Stimulate Adoptively
Transferred T Cells In Vivo
Patrick Hwu, MD MD Anderson Cancer Center |
| 2:00 pm - 2:30 pm | Tumor Antigen Immunization of Human Allotransplant Donors in Myeloma Larry Kwak, MD, PhD MD Anderson Cancer Center |
| 2:30 pm - 3:00 pm | Exploiting Lymphopenia to Reboot the Immune Response to Cancer Bernard A. Fox, PhD Earle A. Chiles Research Institute |
| 3:15 pm - 5:30 pm | Concurrent Session I: Cancer Biometrics Review Chair(s) Michael T. Lotze, MD University of Pittsburgh School of Medicine George Coukos, MD, PhD University of Pennsylvania Medical Center |
| 3:15 pm - 3:30 pm |
Where’s the Rub — Really Useful Biomarkers in Cancer Michael T. Lotze, MD University of Pittsburgh School of Medicine |
| 3:30 pm - 4:00 pm | Clinical Proteomics: Applications at the Bedside Julia Wulfkuhle, MD Division of Therapeutic Products/CBER/FDA |
| 4:00 pm - 4:30 pm |
Bioinformatical Data Reduction Approaches for High Dimensional Data
Derived from High Throughput Assays Yu Shyr, MD Vanderbilt University School of Medicine |
| 4:30 pm - 4:45 pm | Flow Cytometric Monitoring of Jak-STAT Signal Transduction Within
Melanoma Cells Gregory B. Lesinski, PhD The Ohio State University |
| 4:45 pm - 5:00 pm |
Characterizing Complete Responders to IL-2 Using Gene Expression Analysis
and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma Allan Pantuck, MD University of California Los Angeles |
| 5:00 pm - 5:15 pm |
Gene Expression Patterns Associated with Renal Cancer (RCC) Response and
Resistance to IL-2-Based Therapy Philip G. Febbo, MD Duke Institute for Genome Science and Policy |
| 5:15 pm - 5:30 pm |
Markers from the Tumor Microenvironment. Are They Useful?
George Coukos, MD, PhD University of Pennsylvania Medical Center |
| 3:30 pm - 5:15 pm | Concurrent Session II: Dendritic Cells and Vaccines Chair(s) Craig L. Slingluff, Jr., MD University of Virginia Jeffrey S. Weber, MD, PhD University of Southern California Norris Cancer Center |
| 3:30 pm - 3:45 pm | Dacarbacine (DTIC) Versus Vaccination with Autologous Peptide-Pulsed
Dendritic Cells (DC) in First-Line Treatment of Patients with Metastatic
Melanoma: Results of a Multicenter Prospective Randomized Phase III Study Dirk Schadendorf, MD German Cancer Research Center |
| 3:45 pm - 4:00 pm |
Strategies to Augment the Efficacy of Dendritic Cell-Based Vaccines Johannes Vieweg, MD FACS Duke University |
| 4:00 pm - 4:15 pm | Invited Speaker Q&A |
| 4:15 pm - 4:30 pm | Treatment of Metastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed
Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation Richard J. Barth, Jr., MD Dartmouth-Hitchcock Medical Center |
| 4:30 pm - 4:45 pm |
A Randomized Placebo-Controlled Phase II Study with the Cancer Vaccine
IGN101 in Patients with Epithelial Cancers Marc Salzberg Pharma Brains, Ltd. |
| 4:45 pm - 5:00 pm | Vaccination of Patients with Recurrent AML with WT1-Peptide Induces
Clinical and Molecular Remissions as Well as Specific Memory and Effector T
Cells in Perhipheral Blood and Bone Marrow Anne Letsch, MD Charité Campus Benjamin Franklin |
| 5:00 pm - 5:15 pm |
Multipeptide Vaccines for Melanoma: Strategies for Increasing the Breadth of
the T Cell Repertoire Craig L. Slingluff, Jr., MD University of Virginia |
| Saturday, November 6, 2004 | |
| 8:15 am - 9:00 am | Keynote Address Regulatory T Cells: Friend or Foe Ethan Shevach, MD National Institutes of Health |
| 9:00 am - 11:45 am | Plenary Session: Mechanisms of Escape/Resistance Chair(s) Thomas Gajewski, MD, PhD University of Chicago Medical School David Munn, MD Medical College of Georgia |
| 9:00 am - 9:15 am |
Cross Resistance of Melanoma Cells to Apoptosis Induced by Trail and
Chemotherapy Peter Hersey, MD, PhD Newcastle Mater Hospital |
| 9:15 am - 9:30 am | MYCN Regulates CCL2/MCP-1 Production in Neuroblastoma Cells: A
Mechanism of Tumor Escape and a Target for Immunotherapy Liping Song, PhD Childrens Hospital Los Angeles |
| 9:30 am - 10:00 am |
Mechanisms of Resistance to Anti-Tumor Immunity Downstream from Initial
T Cell Priming Thomas Gajewski, MD, PhD University of Chicago Medical School |
| 10:00 am - 10:15 am |
Melanoma Gene Expression Profiles To Identify Mechanisms of Tumor
Resistance to a Multi-Peptide/IL-12 Vaccine Helena A. Harlin, PhD University of Chicago |
| 10:45 am - 11:15 am | Tryptophan Catabolism and Tumor Immune Evasion David Munn, MD Medical College of Georgia |
| 11:15 am - 11:45 am | Changing Battlefields: Bring Immune Response Into Tumor Site Yang-Xin Fu, MD, PhD University of Chicago |
| 11:45 am - 1:00 pm | Even Number Poster Presentations/Box Lunches |
| 1:00 pm - 2:20 pm | Plenary Session: iSBTc Presidential Session Chair Michael B. Atkins, MD Beth Israel Deaconess Medical Center |
| 1:00 pm - 1:20 pm |
Tumor-Infiltrating Dendritic Cell Precursors Recruited by a β-Defensin
Contribute to Vasculogenesis Under the Influence of VEGF-A in Ovarian
Cancer Jose Ramon Conejo-Garcia, MD, PhD University of Pennsylvania |
| 1:20 pm - 1:40 pm | Imiquimod Treatment In Vivo Induces Massive Skin Recruitment and
Activation of Plasmacytoid Dendritic Cells in a Disease-Independent Manner Mirjana Urosevic, MD University Hospital Zurich |
| 1:40 pm - 2:00 pm | CpG in the Immunotherapy of B Cell Lymphoma in an Animal Model Jiali Li, PhD (Presidential Award Winner) Stanford University |
| 2:00 pm - 2:20 pm | Acquisition of Terminal Effector Functions In Vitro Impairs In Vivo Anti-
Tumor Efficacy Luca Gattinoni, MD (Presidential Award Winner) National Cancer Institute - Surgery Branch |
| 2:30 pm - 4:00 pm | Concurrent Session I: Poster Presentations
2:30 pm - 3:15 pm Odd Number Poster Session 3:15 pm - 4:00 pm Even Number Poster Session |
| 2:45 pm - 4:15 pm | Concurrent Session II: Cytokines Chair(s) Jared A. Gollob, MD Duke University Medical Center Steven Dubinett, MD University of California Los Angeles Lung Cancer Research Program |
| 2:45 pm - 3:15 pm |
Cyclooxygenase-2 Regulates Cytokine Balance and Apoptosis Resistance in
Non-Small Cell Lung Cancer Steven Dubinett, MD University of California Los Angeles Lung Cancer Research Program |
| 3:15 am - 3:30 pm | Expression of CXC Chemokines During IL-2 Therapy Correlates with Response
in Metastatic Renal Cell Carcinoma Karen Riedl, MD University of California Los Angeles, David Geffen School of Medicine |
| 3:30 pm - 3:45 pm |
Grade 4 Thrombocytopenia During Treatment with High-Dose Interleukin-2 Is
a Predictor of Response in Melanoma But Not in Renal Cell Cancer Timothy E. Bael, MD Duke University Medical Center |
| 3:45 pm - 4:15 pm |
Use of DNA Microarray Analysis to Identify Genes and Signaling Pathways
Central to the Anti-Melanoma Effect of Interferon-ã Jared A. Gollob, MD Duke University Medical Center |
| 4:00 pm - 5:00 pm | Poster Discussion Session I |
| 4:00 pm - 4:20 pm |
Discussion on Dendritic Cells and Vaccines Howard L. Kaufman, MD New York Presbyterian Hospital -Columbia Campus |
| 4:20 pm - 4:35 pm |
Discussion on Mechanisms of Escape/Resistance James W. Mier, MD Beth Israel Deaconess Medical Center |
| 4:35 pm - 4:50 pm |
Discussion on Adoptive Immunotherapy James W. Young, MD Memorial Sloan-Kettering Cancer Center |
| 4:50 pm - 5:00 pm | General Discussion |
| 4:30 pm - 5:00 pm | Poster Discussion Session II |
| 4:30 pm - 4:45 pm |
Discussion on Antibody Therapy George J. Weiner, MD University of Iowa |
| 4:45 pm - 5:00 pm |
Discussion on Natural Killer Cells & Innate Immunity Theresa L. Whiteside, PhD University of Pittsburgh Cancer Institute |
| Sunday, November 7, 2004 | |
| 8:00 am - 11:00 am | Plenary Session: New Agents in Development - Sponsored by Antigenics Chair(s) Steven J. O’Day, MD John Wayne Cancer Center Gary R. Jones, MD Berlex Laboratories |
| 8:00 am - 8:30 am | Epigenetic Therapy Peter Jones, PhD University of Southern California Norris Comprehensive Cancer Center |
| 8:30 am - 8:45 am | Heat Shock Protein-Based Immunotherapy of Cancer Alem Truneh, PhD Antigenics, Inc. |
| 8:45 am - 9:15 am | Interleukin-21 Elicits Durable T and NK Cytotoxicity: Basic Biology to Clinical
Trials Pallavur V. Sivakumar, PhD Zymogenetics, Inc. |
| 9:15 am - 9:30 am |
Threshold of Credibility: A New Approach to Product Development for
Metastatic Melanoma Therapy Steven Hirschfeld, MD, PhD FDA Office of Cellular, Tissue and Gene Therapies |
| 9:30 am - 9:45 am |
T-Cell Independent Activity of Talabostat (PT-100) Against Human Tumor
Xenografts in Mice Barry Jones, PhD Point Therapeutics |
| 9:45 am - 10:00 am |
AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer
Function James B. Breitmeyer, MD, PhD Applied Molecular Evolution, Inc. |
| 10:00 am - 10:15 am | Enhancement of Anti-Tumor Efficacy of Paclitaxel by CpG ODN; TLR9 Agonist
in Metastatic Murine Cancer Models Risini D. Weeratna, PhD Coley Pharmaceutical Group |
| 10:15 am - 10:30 am |
Therapeutic Efficacy of Gc Protein-Derived Macrophage Activating Factor
(GcMAF) for Adenocarcinoma Nobuto Yamamoto, PhD Socrates Institute for Therapeutic Immunology |
| 10:30 am - 10:45 am |
A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or
Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of
the Children’s Oncology Group
Kaci L. Osenga, MD University of Wisconsin Comprehensive Cancer Center |
| 10:45 am - 11:00 am | Proteasome Inhibition To Maximize the Apoptotic Potential of Cytokine
Therapy for Murine Neuroblastoma Tumors Tahira Khan, PhD National Cancer Institute |